Jori Taylor, APRN
Family · Jacksonville, FLNPI 1508530981
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,177 of the $48,154 with a category attached, or 62.7%. 30 manufacturers reported payments, led by Johnson & Johnson at 58.9% of the total. 2025 is the largest year on record at $30,704, more than ten times the $603 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 789 payments — averaging $61.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$28K
- AbbVie$11K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sanofi$593
- Phathom Pharmaceuticals, Inc.$522
- plus $5K from 24 others
What the payments were for
- Speaking & faculty fees$30,17763%
- Travel & lodging$3,0186%
- Food & beverage$14,88331%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 126 | $28,364 |
| AbbVie | 234 | $11,387 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 89 | $1,478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $1,126 |
| Sanofi | 27 | $593 |
| Phathom Pharmaceuticals, Inc. | 20 | $522 |
| Regeneron Healthcare Solutions, Inc. | 21 | $490 |
| Lilly USA, LLC | 19 | $471 |
| QOL Medical, LLC | 19 | $444 |
| Aimmune Therapeutics, Inc. | 22 | $426 |
| Bristol Myers Squibb | 30 | $421 |
| Madrigal Pharmaceuticals | 22 | $326 |
| Merck | 14 | $289 |
| Ironwood Pharmaceuticals, Inc | 16 | $271 |
| Janssen Scientific Affairs, LLC | 3 | $266 |
| Gilead | 9 | $202 |
| Ardelyx, Inc. | 9 | $156 |
| Pfizer | 8 | $127 |
| Alnylam Pharmaceuticals Inc. | 4 | $110 |
| Nestle Healthcare Nutrition Inc. | 7 | $108 |
| Enterra Medical, Inc. | 4 | $95 |
| Vivus LLC | 5 | $89 |
| Intercept Pharmaceuticals, Inc. | 6 | $87 |
| Ipsen Biopharmaceuticals, Inc | 4 | $83 |
| Redhill Biopharma Inc. | 4 | $69 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Amgen | 2 | $45 |
| Celltrion USA Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,154 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 28 | $129,956 |
| OcalivaObeticholic Acid | 13 | $125,405 |
| LinzessLinaclotide | 94 | $75,584 |
| CreonLipase/Protease/Amylase | 32 | $72,900 |
| VoqueznaVonoprazan Fumarate | 17 | $15,462 |
| TrulancePlecanatide | 14 | $10,850 |
| Mesalamine | 19 | $10,311 |
| MovantikNaloxegol Oxalate | 14 | $8,968 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 73 | $4,452 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 29 | $4,089 |
| Omeprazole | 240 | $3,979 |
| Pantoprazole Sodium | 304 | $3,184 |
| Budesonide DrBudesonide | 21 | $2,945 |
| Cholestyramine LightCholestyramine | 15 | $1,811 |
| Famotidine | 76 | $1,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $11,387 | $148,484126 claims |
| Aimmune Therapeutics, Inc.Zenpep | $426 | $129,95628 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $87 | $125,40513 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $522 | $15,46217 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu | $1,478 | $14,93943 claims |
| Redhill Biopharma Inc.Movantik | $69 | $8,96814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Jacksonville
- Leighanne MeadeJacksonville$98K
- Macy SaundersJacksonville$30K
- Amy KadlubowskiJacksonville$29K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.